|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rabut G and Peter M: Function and
regulation of protein neddylation. ‘Protein modifications: Beyond
the usual suspects’ review series. EMBO Rep. 9:969–976. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Enchev RI, Schulman BA and Peter M:
Protein neddylation: Beyond cullin-RING ligases. Nat Rev Mol Cell
Biol. 16:30–44. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhao Y, Morgan MA and Sun Y: Targeting
neddylation pathways to inactivate cullin-RING ligases for
anticancer therapy. Antioxid Redox Signal. 21:2383–2400. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu J, Li L, Yu G, Ying W, Gao Q, Zhang W,
Li X, Ding C, Jiang Y, Wei D, et al: The neddylation-cullin 2-RBX1
E3 ligase axis targets tumor suppressor RhoB for degradation in
liver cancer. Mol Cell Proteomics. 14:499–509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li L, Wang M, Yu G, Chen P, Li H, Wei D,
Zhu J, Xie L, Jia H, Shi J, et al: Overactivated neddylation
pathway as a therapeutic target in lung cancer. J Natl Cancer Inst.
106:dju0832014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xie P, Zhang M, He S, Lu K, Chen Y, Xing
G, Lu Y, Liu P, Li Y, Wang S, et al: The covalent modifier Nedd8 is
critical for the activation of Smurf1 ubiquitin ligase in
tumorigenesis. Nat Commun. 5:37332014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soucy TA, Smith PG, Milhollen MA, Berger
AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP,
Critchley S, et al: An inhibitor of NEDD8-activating enzyme as a
new approach to treat cancer. Nature. 458:732–736. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D,
Pan Y, Ding C, Qian J, Wu L, et al: The Nedd8-activating enzyme
inhibitor MLN4924 induces autophagy and apoptosis to suppress liver
cancer cell growth. Cancer Res. 72:3360–3371. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao Q, Yu GY, Shi JY, Li LH, Zhang WJ,
Wang ZC, Yang LX, Duan M, Zhao H, Wang XY, et al: Neddylation
pathway is up-regulated in human intrahepatic cholangiocarcinoma
and serves as a potential therapeutic target. Oncotarget.
5:7820–7832. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hua W, Li C, Yang Z, Li L, Jiang Y, Yu G,
Zhu W, Liu Z, Duan S, Chu Y, et al: Suppression of glioblastoma by
targeting the overactivated protein neddylation pathway. Neuro
Oncol. 17:1333–1343. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen P, Hu T, Liang Y, Jiang Y, Pan Y, Li
C, Zhang P, Wei D, Li P, Jeong LS, et al: Synergistic inhibition of
autophagy and neddylation pathways as a novel therapeutic approach
for targeting liver cancer. Oncotarget. 6:9002–9017.
2015.PubMed/NCBI
|
|
15
|
Wei D, Li H, Yu J, Sebolt JT, Zhao L,
Lawrence TS, Smith PG, Morgan MA and Sun Y: Radiosensitization of
human pancreatic cancer cells by MLN4924, an investigational
NEDD8-activating enzyme inhibitor. Cancer Res. 72:282–293. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li H, Zhou W, Li L, Wu J, Liu X, Zhao L,
Jia L and Sun Y: Inhibition of neddylation modification sensitizes
pancreatic cancer cells to gemcitabine. Neoplasia. 19:509–518.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feldman JP, Goldwasser R, Mark S, Schwartz
J and Orion I: A mathematical model for tumor volume evaluation
using two-dimensions. J Appl Quant Methods. 4:455–462. 2009.
|
|
19
|
Roos WP and Kaina B: DNA damage-induced
cell death by apoptosis. Trends Mol Med. 12:440–450. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Milhollen MA, Traore T, Adams-Duffy J,
Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E,
Langston SP, et al: MLN4924, a NEDD8-activating enzyme inhibitor,
is active in diffuse large B-cell lymphoma models: Rationale for
treatment of NF-{kappa}B-dependent lymphoma. Blood. 116:1515–1523.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin JJ, Milhollen MA, Smith PG, Narayanan
U and Dutta A: NEDD8-targeting drug MLN4924 elicits DNA
rereplication by stabilizing Cdt1 in S phase, triggering checkpoint
activation, apoptosis, and senescence in cancer cells. Cancer Res.
70:10310–10320. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao Y, Xiong X, Jia L and Sun Y:
Targeting Cullin-RING ligases by MLN4924 induces autophagy via
modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Cell Death Dis.
3:e3862012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Blank JL, Liu XJ, Cosmopoulos K, Bouck DC,
Garcia K, Bernard H, Tayber O, Hather G, Liu R, Narayanan U, et al:
Novel DNA damage checkpoints mediating cell death induced by the
NEDD8-activating enzyme inhibitor MLN4924. Cancer Res. 73:225–234.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin S, Shang Z, Li S, Gao P, Zhang Y, Hou
S, Qin P, Dong Z, Hu T and Chen P: Neddylation inhibitor MLN4924
induces G2 cell cycle arrest, DNA damage and sensitizes
esophageal squamous cell carcinoma cells to cisplatin. Oncol Lett.
15:2583–2589. 2018.PubMed/NCBI
|
|
25
|
Li JA, Song C, Rong Y, Kuang T, Wang D, Xu
X, Yuan J, Luo K, Qin B, Nowsheen S, et al: Chk1 inhibitor SCH
900776 enhances the antitumor activity of MLN4924 on pancreatic
cancer. Cell Cycle. 17:191–199. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cope GA and Deshaies RJ: COP9 signalosome:
A multifunctional regulator of SCF and other cullin-based ubiquitin
ligases. Cell. 114:663–671. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fukumoto A, Ikeda N, Sho M, Tomoda K,
Kanehiro H, Hisanaga M, Tsurui Y, Tsutsumi M, Kato JY and Nakajima
Y: Prognostic significance of localized p27Kip1 and potential role
of Jab1/CSN5 in pancreatic cancer. Oncol Rep. 11:277–284.
2004.PubMed/NCBI
|
|
28
|
Pan Y and Claret FX: Targeting Jab1/CSN5
in nasopharyngeal carcinoma. Cancer Lett. 326:155–160. 2012.
View Article : Google Scholar : PubMed/NCBI
|
